Fiduciary Family Office LLC Acquires 88 Shares of Thermo Fisher Scientific Inc. $TMO

Fiduciary Family Office LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,015 shares of the medical research company’s stock after purchasing an additional 88 shares during the period. Fiduciary Family Office LLC’s holdings in Thermo Fisher Scientific were worth $412,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific in the first quarter worth $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific in the first quarter worth $31,000. DiNuzzo Private Wealth Inc. lifted its position in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after acquiring an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its position in Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after acquiring an additional 45 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $559.48 on Wednesday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $211.27 billion, a PE ratio of 32.36, a price-to-earnings-growth ratio of 3.14 and a beta of 0.77. The firm has a 50-day moving average price of $499.00 and a 200 day moving average price of $450.49.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the business posted $5.37 earnings per share. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on TMO shares. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, October 12th. Barclays boosted their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 24th. UBS Group boosted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Finally, Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating for the company in a research report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $581.72.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock valued at $14,182,963 over the last quarter. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.